# The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

> **NCT02573636** · — · RECRUITING · sponsor: **Sir Mortimer B. Davis - Jewish General Hospital** · enrollment: 208 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02573636
- **Lead sponsor:** Sir Mortimer B. Davis - Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2016-03
- **Primary completion:** 2026-11
- **Final completion:** 2027-03
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573636, "The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02573636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*